Trailblazing Medical Cannabis with Cantourage's Philip Schetter | Startuprad.io E 415

Executive Summary In this episode of Startuprad.io host Jörn "Joe" Menninger speaks with guest Philip Schetter, CEO of Cantourage, about the company's role in the expanding medical cannabis industry in Europe. Schetter discusses Cantourage's growth, manufacturing processes, digital platform for wholesalers, and market reach. The company, recently public on the Frankfurt Stock Exchange, is hiring talents and is focused on the medical market, with a cautious stance on recreational legalization. Cantourage sources globally and distributes across Europe, navigating complex regulations and investor interests, while Germany's market potential looms large. Interested listeners are directed to Cantourage's LinkedIn and career site in the show notes. Disclaimer - Since Cantourage is Listed The interview conducted by Startuprad.io with Cantourage is not a paid promotion nor a recommendation to purchase their listed shares. Financial decisions should be made with caution and after thorough consideration, including conducting personal research and consulting with an investment professional. The information provided in the interview is for informational purposes only and does not constitute financial advice. Interested in Working with us? Have a look here: https://www.passionfroot.me/startupradio Subscribe Here https://linktr.ee/startupradio Our Sponsor Startupraven The best way to find investors and cooperation partners for early-stage startups. Sign up here: https://startupraven.com/ Introduction Welcome back to another episode of Startuprad.io - the engaging podcast where we bring light to the brightest innovations and startups. We're joined by a very special guest, Philip Schetter, CEO of Cantourage, who will share insights into how this burgeoning company is revolutionizing the cannabis market. Cantourage, now a proud member of the Frankfurt Stock Exchange family, is on the lookout for fresh talent across Berlin, Bavaria, and Europe to support its growth. In our conversation, Philip will uncover the important shift in Germany's medical cannabis regulation - no longer seen as a narcotic, but now recognized as prescription medicine - and discuss the nuances of a cautious approach towards the potential legalization of recreational use. We'll explore the sophisticated mechanisms Cantourage employs to produce high-quality medicines right from their hub in Bavaria, using innovative methods to ensure purity and efficacy, shunning the traditional irradiation techniques. Ever wondered how pharmacies might navigate the complex world of medical cannabis ordering? Cantourage has the answer with their cutting-edge, fully digitized platform, designed to streamline the wholesale process. With a commanding presence across multiple product formats, Cantourage claims a substantial share of the medical cannabis market. Philip's path to CEO of Cantourage is as intriguing as the industry itself, involving a history of cultivating success at another business giant, Aurora Deutschland GmbH. Listeners with an ear for financial strategy will find Philip's insights into going public particularly riveting. We'll delve into how this move not only adds a layer of complexity but also elevates the company's professional and transparent stance - factors that are increasingly attracting the sharp eyes of institutional investors. Despite the buzz and speculation around recreational cannabis, Cantourage stands firm in its focus on the medical market, citing significant prospects for growth.